Spots Global Cancer Trial Database for btk inhibitor
Every month we try and update this database with for btk inhibitor cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies | NCT05275504 | B-Cell Malignan... | TT-01488 | 18 Years - | TransThera Sciences (Nanjing), Inc. | |
| Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma | NCT05820841 | Large B-cell Ly... Diffuse Large B... | R-miniCHOP + Ac... R-miniCHOP | 61 Years - | Universität des Saarlandes | |
| Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies | NCT05275504 | B-Cell Malignan... | TT-01488 | 18 Years - | TransThera Sciences (Nanjing), Inc. | |
| Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia | NCT04624906 | Waldenstrom Mac... | Acalabrutinib Bendamustine Rituximab | 18 Years - | Sunnybrook Health Sciences Centre | |
| A Study of NX-5948 in Adults With Relapsed/Refractory B-cell Malignancies | NCT05131022 | Chronic Lymphoc... Small Lymphocyt... Diffuse Large B... Follicular Lymp... Mantle Cell Lym... Marginal Zone L... Waldenstrom Mac... Primary Central... | NX-5948 | 18 Years - | Nurix Therapeutics, Inc. | |
| Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia | NCT01351935 | B Cell Non-Hodg... Chronic Lymphoc... Waldenstrom Mac... | AVL-292 | 18 Years - | Celgene | |
| Escalating Dose Study in Subjects With Relapsed or Refractory B Cell Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and Waldenstrom's Macroglobulinemia | NCT01351935 | B Cell Non-Hodg... Chronic Lymphoc... Waldenstrom Mac... | AVL-292 | 18 Years - | Celgene | |
| Orelabrutinib Combined With Pemetrexed For Relapsed/Refractory Central Nervous System Lymphoma | NCT05209620 | Central Nervous... | ICP-022 Pemetrexed | 18 Years - 75 Years | Henan Cancer Hospital | |
| Expanded Access Program for Pirtobrutinib for Participants With B-Cell Cancer | NCT05172700 | Leukemia, Lymph... Lymphoma, Lymph... Lymphoma, Mantl... Waldenstrom Mac... Ritcher's Trans... | Pirtobrutinib | 18 Years - | Eli Lilly and Company | |
| LV20.19 CAR T-Cells in Combination With Pirtobrutinib for Relapsed, Refractory B-cell Malignancies | NCT05990465 | Non Hodgkin Lym... Diffuse Large B... Follicular Lymp... Marginal Zone L... Mantle Cell Lym... Burkitt Lymphom... | Pirtobrutinib LV20.19 CAR T c... | 18 Years - 81 Years | Medical College of Wisconsin | |
| Study to Evaluate the Safety and Tolerability of TT-01488 in Patients With B-Cell Malignancies | NCT05275504 | B-Cell Malignan... | TT-01488 | 18 Years - | TransThera Sciences (Nanjing), Inc. | |
| Pilot Study to Determine Effects of the Btk Inhibitor PCI-32765 on Leukemia Cell Kinetics and Trafficking, Using Heavy Water Labeling in Subjects With CLL and SLL | NCT01752426 | Leukemia | Heavy Water (2H... PCI-32765 | 18 Years - | M.D. Anderson Cancer Center | |
| Acalabrutinib With DA-EPOCH-R or R-CHOP for People With Untreated Diffuse Large B-cell Lymphoma | NCT04002947 | Non-Hodgkin's L... Diffuse Large B... DLBCL NHL | DA-EPOCH Rituximab CHOP Acalabrutinib | 18 Years - | National Institutes of Health Clinical Center (CC) | |
| Acalabrutinib in Combination With R-miniCHOP in Older Adults With Untreated Diffuse Large B-Cell Lymphoma | NCT05820841 | Large B-cell Ly... Diffuse Large B... | R-miniCHOP + Ac... R-miniCHOP | 61 Years - | Universität des Saarlandes | |
| Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia | NCT02165397 | Waldenström's M... | Ibrutinib Placebo Rituximab | 18 Years - | Pharmacyclics LLC. | |
| A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | NCT05023980 | Chronic Lymphoc... Small Lymphocyt... | Pirtobrutinib Bendamustine Rituximab | 18 Years - | Eli Lilly and Company | |
| Bendamustine, Rituximab and Acalabrutinib in Waldenstrom's Macroglobulinemia | NCT04624906 | Waldenstrom Mac... | Acalabrutinib Bendamustine Rituximab | 18 Years - | Sunnybrook Health Sciences Centre | |
| Ibrutinib With Rituximab in Adults With Waldenström's Macroglobulinemia | NCT02165397 | Waldenström's M... | Ibrutinib Placebo Rituximab | 18 Years - | Pharmacyclics LLC. | |
| A Prospective Clinical Study of BTK Inhibitor, PD-1 and Formustine in the First-line Treatment of Primary Central Nervous System Lymphoma | NCT04831658 | Primary Central... | the dose-escala... | 18 Years - 69 Years | Zhengzhou University | |
| A Prospective Clinical Study of BTK Inhibitor, PD-1 and Formustine in the First-line Treatment of Primary Central Nervous System Lymphoma | NCT04831658 | Primary Central... | the dose-escala... | 18 Years - 69 Years | Zhengzhou University | |
| Clinical Study of the Safety and Efficacy of the R/R B-NHL Regimen With BTK Inhibitor+Anti-CD19 CAR-T Cells | NCT05744037 | B-cell Non Hodg... | regimen with BT... | 18 Years - 70 Years | The Affiliated Hospital of Xuzhou Medical University | |
| A Combination Study of CAR-T Therapy in r/r B-NHL | NCT05871684 | Diffuse Large B... | BTK inhibitor PD-1 inhibitor | 18 Years - | Ruijin Hospital | |
| A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) | NCT05023980 | Chronic Lymphoc... Small Lymphocyt... | Pirtobrutinib Bendamustine Rituximab | 18 Years - | Eli Lilly and Company | |
| A Study of NX-2127 in Adults With Relapsed/Refractory B-cell Malignancies | NCT04830137 | Chronic Lymphoc... Small Lymphocyt... Waldenstrom Mac... Mantle Cell Lym... Marginal Zone L... Follicular Lymp... Diffuse Large B... Primary Central... | NX-2127 | 18 Years - | Nurix Therapeutics, Inc. |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
